JP2019521156A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521156A5
JP2019521156A5 JP2019502063A JP2019502063A JP2019521156A5 JP 2019521156 A5 JP2019521156 A5 JP 2019521156A5 JP 2019502063 A JP2019502063 A JP 2019502063A JP 2019502063 A JP2019502063 A JP 2019502063A JP 2019521156 A5 JP2019521156 A5 JP 2019521156A5
Authority
JP
Japan
Prior art keywords
patient
pharmaceutical composition
secukinumab
weeks
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019502063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521156A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/054333 external-priority patent/WO2018015880A1/en
Publication of JP2019521156A publication Critical patent/JP2019521156A/ja
Publication of JP2019521156A5 publication Critical patent/JP2019521156A5/ja
Priority to JP2022100449A priority Critical patent/JP2022126791A/ja
Priority to JP2023172063A priority patent/JP2024001125A/ja
Priority to JP2025058479A priority patent/JP2025102888A/ja
Pending legal-status Critical Current

Links

JP2019502063A 2016-07-19 2017-07-18 Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 Pending JP2019521156A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022100449A JP2022126791A (ja) 2016-07-19 2022-06-22 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2023172063A JP2024001125A (ja) 2016-07-19 2023-10-03 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2025058479A JP2025102888A (ja) 2016-07-19 2025-03-31 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364007P 2016-07-19 2016-07-19
US62/364,007 2016-07-19
PCT/IB2017/054333 WO2018015880A1 (en) 2016-07-19 2017-07-18 Methods of treating new-onset plaque type psoriasis using il-17 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022100449A Division JP2022126791A (ja) 2016-07-19 2022-06-22 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法

Publications (2)

Publication Number Publication Date
JP2019521156A JP2019521156A (ja) 2019-07-25
JP2019521156A5 true JP2019521156A5 (enExample) 2020-08-27

Family

ID=59677269

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019502063A Pending JP2019521156A (ja) 2016-07-19 2017-07-18 Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2022100449A Withdrawn JP2022126791A (ja) 2016-07-19 2022-06-22 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2023172063A Pending JP2024001125A (ja) 2016-07-19 2023-10-03 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2025058479A Pending JP2025102888A (ja) 2016-07-19 2025-03-31 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022100449A Withdrawn JP2022126791A (ja) 2016-07-19 2022-06-22 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2023172063A Pending JP2024001125A (ja) 2016-07-19 2023-10-03 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2025058479A Pending JP2025102888A (ja) 2016-07-19 2025-03-31 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法

Country Status (6)

Country Link
US (2) US20190194311A1 (enExample)
EP (2) EP4477265A3 (enExample)
JP (4) JP2019521156A (enExample)
CN (1) CN109476733A (enExample)
ES (1) ES2992409T3 (enExample)
WO (1) WO2018015880A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018015880A1 (en) * 2016-07-19 2018-01-25 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
EP4006053A4 (en) * 2019-07-30 2022-10-26 Jiangsu Hengrui Medicine Co., Ltd. METHOD OF TREATMENT OF AUTOIMMUNE DISEASE BY IL-17 ANTAGONISTS
EP3797779A1 (en) * 2019-09-30 2021-03-31 Servei de Salut de Les Illes Balears - Ibsalut Combined therapy comprising an inhibitor of interleukin-17 activity and a vitamin d receptor agonist
CN114746444A (zh) * 2019-12-06 2022-07-12 诺华股份有限公司 使用白介素-17(il-17)拮抗剂治疗扁平苔藓的方法
CN113855807A (zh) * 2021-10-25 2021-12-31 孙良丹 一种试剂在制备治疗/抑制银屑病药物中的应用
WO2025222170A1 (en) * 2024-04-19 2025-10-23 Zb17 Llc Methods of treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
LT2481753T (lt) 2005-12-13 2018-05-25 Eli Lilly And Company Anti-il-17 antikūnai
RU2430110C2 (ru) 2006-01-31 2011-09-27 Новартис Аг Антитела - антагонисты интерлейкина-17 (ил-17) для лечения рака
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
KR101318549B1 (ko) 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
PT2625199T (pt) * 2010-10-08 2018-02-28 Novartis Ag Métodos de tratamento de psoríase usando antagonistas de il-17
US20140359902A1 (en) 2011-12-16 2014-12-04 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
SI2953969T1 (sl) 2013-02-08 2020-01-31 Novartis Ag Protitelesa proti-IL-17A in njihova uporaba v zdravljenju avtoimunskih in vnetnih motenj
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
US10434172B2 (en) 2013-08-15 2019-10-08 Novartis Ag Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2018015880A1 (en) * 2016-07-19 2018-01-25 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists

Similar Documents

Publication Publication Date Title
JP2019521156A5 (enExample)
CN103458926B (zh) 改进的高浓度抗TNF α 抗体液体制剂
JP6554155B2 (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
RU2008141433A (ru) Терапия опухолей с использованием сосудистого эндотелиального фактора роста и антитела к рецептору типа 2 человеческого эпителиального фактора роста
JP2020510039A5 (enExample)
JP2016505572A5 (enExample)
JP2024001125A (ja) Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
RU2012108108A (ru) Концентрированные полипептидные лекарственные формы с пониженной вязкостью
JP2009538916A5 (enExample)
KR20200083996A (ko) 인터류킨-17(il-17)을 사용하여 건병증을 치료하는 방법
US20250122270A1 (en) Intradermal administration of immunoglobulin g preparation
JP2005529152A5 (enExample)
RU2019108441A (ru) Режим дозирования
WO2021018191A1 (zh) Il-17拮抗剂治疗自身免疫疾病的方法
CA3187136A1 (en) Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists
RU2023102788A (ru) Лечение гнойного гидраденита с использованием антагонистов il-17
JPWO2019186369A5 (enExample)
RU2020134794A (ru) Способы лечения хронической спонтанной крапивницы с применением лигелизумаба
JP2020517648A5 (enExample)
US20190345246A1 (en) Compositions and Methods for Treating Autoimmune Inner Ear Disease
TW202241505A (zh) 抗il-17抗體治療自體免疫性疾病和炎症的方法
JPWO2023099668A5 (enExample)
NZ760588B2 (en) Methods for Treating TNFa-Related Diseases
NZ775405B2 (en) Humanized antibodies against c-kit